TY - JOUR
T1 - Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
AU - Larsen, Kristin
AU - Spencer, Horace
AU - Mohan, Meera
AU - Bailey, Clyde
AU - Hill, Kerri
AU - Kottarathara, Mathew
AU - Parikh, Richa
AU - Hoque, Shadiqul
AU - Erra, Amani
AU - Mitma, Angel A.
AU - Mathur, Pankaj
AU - Yarlagadda, Lakshmi
AU - Gundarlapalli, Sravani
AU - Ogunsesan, Yetunde
AU - Hussain, Munawwar
AU - Thalambedu, Nishanth
AU - Sehti, Jaskirat
AU - Hadidi, Samer Al
AU - Thanendrarajan, Sharmilan
AU - Graziutti, Monica
AU - Zangari, Maurizio
AU - Barlogie, Bart
AU - van Rhee, Frits
AU - Tricot, Guido
AU - Schinke, Carolina
N1 - Funding Information:
Funding: Work completed by C.S. was funded the National Institutes of Health grants P20GM109005. Work completed by H.S. was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1 TR003107.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most patients in the US undergoing inpatient ASCT. Furthermore, hospitalization rates for patients that undergo outpatient ASCT remain high. Adequate markers that predict hospitalization during outpatient ASCT are lacking, yet would be of great clinical value to select patients that are suited to outpatient ASCT. In this study we aimed to elucidate differences between planned outpatient and inpatient ASCT and further evaluated clinical characteristics that are significantly associated with hospitalization during planned outpatient hospitalization. Factors that were significantly associated with a planned inpatient ASCT included an advanced MM disease stage, worse performance status as well as non-Caucasian race, while low albumin levels and female gender were significantly associated with hospitalization during outpatient ASCT. The results of this analysis provide crucial knowledge of factors that are associated with planned inpatient ASCT and hospitalization during outpatient ASCT and could guide the treating physician in decision-making and further facilitate outpatient transplantation.
AB - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most patients in the US undergoing inpatient ASCT. Furthermore, hospitalization rates for patients that undergo outpatient ASCT remain high. Adequate markers that predict hospitalization during outpatient ASCT are lacking, yet would be of great clinical value to select patients that are suited to outpatient ASCT. In this study we aimed to elucidate differences between planned outpatient and inpatient ASCT and further evaluated clinical characteristics that are significantly associated with hospitalization during planned outpatient hospitalization. Factors that were significantly associated with a planned inpatient ASCT included an advanced MM disease stage, worse performance status as well as non-Caucasian race, while low albumin levels and female gender were significantly associated with hospitalization during outpatient ASCT. The results of this analysis provide crucial knowledge of factors that are associated with planned inpatient ASCT and hospitalization during outpatient ASCT and could guide the treating physician in decision-making and further facilitate outpatient transplantation.
KW - Autologous stem cell transplantation
KW - Hospitalization
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85126571002&partnerID=8YFLogxK
U2 - 10.3390/jcm11061640
DO - 10.3390/jcm11061640
M3 - Article
AN - SCOPUS:85126571002
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 6
M1 - 1640
ER -